Stefan Luzi
Partner @ Gilde Healthcare
Utrecht, The Netherlands
Stefan Luzi is a Series B investor at Gilde Healthcare in Utrecht focused on Biopharma and Therapeutics. Stefan Luzi joined Gilde Healthcare in 2015. He is focusing on the generation and assessment of investment cases in the biopharm, medtech, diagnostics and digital health sectors and supports transaction execution and fund management.Prior to joining Gilde, Stefan worked at Merck KGaA for two years. As part of the Global Graduate Program hecompleted several international assignments, most notably with the Global Business Intelligence and MS Ventures divisions. Additionally, he was involved in various consulting projects spanning the pharmaceutical and chemical departments at Merck and co-moderated Merck Serono’s innovation competitions.Stefan holds a MSc in Biotechnology degree from ETH Zurich (Switzerland) and a MPhil in Bioscience Enterprise degree from the University of Cambridge (UK). He also completed a PhD program with Sir Gregory Winter at the MRC Laboratory of Molecular Biology in Cambridge (UK) where he developed a bicyclic peptide based drug discovery platform.He is a Swiss citizen based in Gilde’s Utrecht office.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Stefan Luzi invests in
Stages Stefan Luzi invests in
Countries Stefan Luzi invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biopharma 1 (50%)
- Therapeutics 1 (50%)
- Biotechnology 1 (50%)
Stage
- Series B 1 (50%)
- Series D 1 (50%)
Country
- Germany 1 (50%)
- United Kingdom 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Catalym develops antibodies against a placental factor which is overexpressed by various tumour types. | $150M / Series D / Jul 16, 2024 | ||
| Amphista Therapeutics operates as a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease causing proteins. | $53M / Series B / Mar 17, 2021 |
Co-Investors
About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Gilde Healthcare Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Edwin Graaf
Managing Partner
|
|||
Joep Muijrers
General Partner
|
|||
Pieter van der Meer
Managing Partner & Founder
|
|||
|
Stefan Luzi
Partner
|
|||
Arthur Franken
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Stefan Luzi invest in?
Stefan Luzi invests primarily in Biopharma, Therapeutics and Biotechnology startups, most often at Series B and Series D stage. Most of the 2 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Stefan Luzi?
Public channels for Stefan Luzi include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Stefan Luzi last invest?
The most recent investment recorded for Stefan Luzi closed in Jul 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
